(Q43944377)

28 November 2017

title

An approach to the treatment of essential hypertension. (English)

1 reference

28 November 2017

Vlachakis ND

1

1 reference

28 November 2017

Mendlowitz M

series ordinal

2

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 December 1976

1 reference

28 November 2017

published in

American Heart Journal

1 reference

28 November 2017

volume

92

1 reference

28 November 2017

issue

6

1 reference

28 November 2017

page(s)

750-757

1 reference

Hemodynamics in Labile Hypertension: A Follow-Up Study

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Re-examination of the hemodynamics of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

VARYING HEMODYNAMIC PATTERNS IN ESSENTIAL HYPERTENSION

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

HEMODYNAMIC PATTERNS IN ESSENTIAL HYPERTENSION

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

CLINICAL EVALUATION OF DIAZOXIDE: A NEW TREATMENT FOR ACUTE HYPERTENSION

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Hemodynamic and therapeutic effects of guancydine in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

The effect of guancydine on blood pressure, vascular reactivity, and norepinephrine uptake in essential hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Clinical experiences with guanethidine in ambulatory hypertensive subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Effects of methyldopa in fifty hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Effect of propranolol in mild hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Hypotensive action of propranolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Effects of propranolol on the pressor response to noxious stimuli in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Adverse reactions to propranolol in hospitalized medical patients: A report from the Boston Collaborative Drug Surveillance Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Nature of the Vasodilator and Vasoconstrictor Receptors in Skeletal Muscle of the Dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

The effect of antagonists on the response of the forearm vessels to adrenaline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

The effect of alpha- and beta-adrenergic blocking agents on the renin response to hypoglycemia and epinephrine in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Alpha- and beta-adrenergic receptor blockade in the treatment of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Alpha and beta adrenergic blockade in hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

A point-score system for the ECG diagnosis of left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Propranolol as an antihypertensive agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Evaluation of the hypotensive effect of beta-adrenergic blockade in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Controlled trial of propranolol in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Management of severe hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Immediate hemodynamic effects of beta-adrenergic blockade with propranolol in normotensive and hypertensive man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Haemodynamic studies in hypertensive patients treated by oral propranolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

On the local reactions of the arterial wall to changes of internal pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Central Hypotensive Activity of dl- and d-Propranolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Twice-daily propranolol treatment for hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Use of dibenzyline as a vasodilator in patients with severe digital ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Blockade of sympathetic vasoconstriction in the treatment of shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Phentolamine for vasodilator treatment of severe heart-failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

7 January 2021

Dibenzyline in Glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Effect of oral 688A (N-phenoxy-isopropyl-N-benzyl-beta-chloroethylamine hydrochloride) on blood pressure in normotensive and hypertensive subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

Changes in glomerular filtration rate during long-term treatment with propranolol in patients with arterial hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

CAUSES OF DEATH IN TREATED HYPERTENSIVE PATIENTS: BASED ON 82 DEATHS DURING 1959-61 AMONG AN AVERAGE HYPERTENSIVE POPULATION AT RISK OF 518 PERSONS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2876%2980012-9

10.1016/S0002-8703(76)80012-9

7 January 2021

Identifiers

DOI

1 reference

28 November 2017

1 reference